Cancer

April 5, 2019

Probiotic-based chemotherapy targeting cancer stem cells and immune-inhibitory receptors in advanced metastatic cancers: A pharmaceutical mixture encompassing a pharmacological formulation encompassing Metformin, Navitoclax/ABT-263, & Dasatinib (MND) and probiotic Lactobacillus rhamnosus increases the expression of tumor suppressor genes, such as BIRC5, PIAS3, p53, and TA-p73/p63, inhibits immune-inhibitory receptors/molecules, targets cancer stem cells, confers protection against chemoresistance and prolongs survival, via up-regulation of its target gene, 5/April/2019, 11.14 pm

Probiotic-based chemotherapy targeting cancer stem cells and immune-inhibitory receptors in advanced metastatic cancers: A pharmaceutical mixture encompassing a pharmacological formulation encompassing Metformin, Navitoclax/ABT-263, & Dasatinib (MND) and probiotic Lactobacillus rhamnosus increases the expression of tumor suppressor genes, such as BIRC5, PIAS3, p53, and TA-p73/p63, inhibits immune-inhibitory receptors/molecules, targets cancer stem cells, confers protection against chemoresistance and prolongs survival, via up-regulation of its target gene, 5/April/2019, 11.14 pm https://genomediscovery.org/wp-content/uploads/2019/04/A-pharmaceutical-mixture-encompassing-Metformin-Navitoclax-and-Dasatinib-MND-functions-as-an-anti-tumor.metastasis-agent-by-increasing-the-expression-of-BIRC5-PIAS3.jpg 960 720 Dr Boomi's Genom-2-Discovery Center Dr Boomi's Genom-2-Discovery Center https://genomediscovery.org/wp-content/uploads/2019/04/A-pharmaceutical-mixture-encompassing-Metformin-Navitoclax-and-Dasatinib-MND-functions-as-an-anti-tumor.metastasis-agent-by-increasing-the-expression-of-BIRC5-PIAS3.jpg April 5, 2019 April 5, 2019

What we say: On the foundation of this interesting finding, Dr L Boominathan PhD, the Director-cum-chief Scientist of GBMD, reports that: Probiotic-based chemotherapy targeting cancer stem cells and immune-inhibitory receptors in…

April 2, 2019

Probiotic-based chemotherapy targeting cancer stem cells and immune-inhibitory receptors in advanced metastatic cancers: A pharmaceutical mixture encompassing a pharmacological formulation encompassing Metformin, Navitoclax/ABT-263, & Dasatinib (MND) and probiotic Lactobacillus rhamnosus increases the expression of tumor suppressor genes, such as PTPN14, SMARCA4, p53, and TA-p73/p63, inhibits immune-inhibitory receptors/molecules, targets cancer stem cells, confers protection against chemoresistance and prolongs survival, via up-regulation of its target gene, 3/April/2019, 12.14 am

Probiotic-based chemotherapy targeting cancer stem cells and immune-inhibitory receptors in advanced metastatic cancers: A pharmaceutical mixture encompassing a pharmacological formulation encompassing Metformin, Navitoclax/ABT-263, & Dasatinib (MND) and probiotic Lactobacillus rhamnosus increases the expression of tumor suppressor genes, such as PTPN14, SMARCA4, p53, and TA-p73/p63, inhibits immune-inhibitory receptors/molecules, targets cancer stem cells, confers protection against chemoresistance and prolongs survival, via up-regulation of its target gene, 3/April/2019, 12.14 am https://genomediscovery.org/wp-content/uploads/2019/04/A-pharmaceutical-mixture-encompassing-MND-and-the-probiotic-Lactobacillus-attenute-tumor-prog-through-induction-of-PTPN14-and-SMARCA4.jpg 960 720 Dr Boomi's Genom-2-Discovery Center Dr Boomi's Genom-2-Discovery Center https://genomediscovery.org/wp-content/uploads/2019/04/A-pharmaceutical-mixture-encompassing-MND-and-the-probiotic-Lactobacillus-attenute-tumor-prog-through-induction-of-PTPN14-and-SMARCA4.jpg April 2, 2019 April 2, 2019

April 1, 2019

An aspirin a day keeps cancer away, if so, what is the mechanism?: Probiotic-based chemotherapy targeting cancer stem cells and immune-inhibitory receptors in advanced metastatic cancers: A pharmaceutical mixture encompassing Aspirin, a nonsteroidal anti-inflammatory drug, and probiotic Lactobacillus rhamnosus increases the expression of tumor suppressor genes, such as TPM1, CCM3/KRIT1, p53, and TA-p73/p63, inhibits immune-inhibitory receptors/molecules, targets ovarian cancer stem cells, confers protection against chemoresistance and prolongs survival, via up-regulation of its target gene, 1/April/2018, 11.19 pm

An aspirin a day keeps cancer away, if so, what is the mechanism?: Probiotic-based chemotherapy targeting cancer stem cells and immune-inhibitory receptors in advanced metastatic cancers: A pharmaceutical mixture encompassing Aspirin, a nonsteroidal anti-inflammatory drug, and probiotic Lactobacillus rhamnosus increases the expression of tumor suppressor genes, such as TPM1, CCM3/KRIT1, p53, and TA-p73/p63, inhibits immune-inhibitory receptors/molecules, targets ovarian cancer stem cells, confers protection against chemoresistance and prolongs survival, via up-regulation of its target gene, 1/April/2018, 11.19 pm https://genomediscovery.org/wp-content/uploads/2019/04/Aspirin-attenuates-tumor-progression-through-induction-of-a-number-of-tumor-supp-genes-inclu.-TPM1-CCM3-INK4a-ARF-PTEN-and-others.jpg 960 720 Dr Boomi's Genom-2-Discovery Center Dr Boomi's Genom-2-Discovery Center https://genomediscovery.org/wp-content/uploads/2019/04/Aspirin-attenuates-tumor-progression-through-induction-of-a-number-of-tumor-supp-genes-inclu.-TPM1-CCM3-INK4a-ARF-PTEN-and-others.jpg April 1, 2019 April 2, 2019

What we say: On the foundation of this interesting finding, Dr L Boominathan PhD, the Director-cum-chief Scientist of GBMD, reports that: An aspirin a day keeps cancer away, if so, what…

March 29, 2019

Probiotic-based chemotherapy targeting cancer stem cells and immune-inhibitory receptors in advanced metastatic cancers: A pharmaceutical mixture encompassing a pharmacological formulation encompassing Metformin, Navitoclax/ABT-263, & Dasatinib (MND) and probiotic Lactobacillus rhamnosus increases the expression of tumor suppressor genes, such as RECK, BTG2, p53, and TA-p73/p63, inhibits immune-inhibitory receptors/molecules, targets cancer stem cells, confers protection against chemoresistance and prolongs survival, via up-regulation of its target gene, 29/March/2019, 11.04 pm

Probiotic-based chemotherapy targeting cancer stem cells and immune-inhibitory receptors in advanced metastatic cancers: A pharmaceutical mixture encompassing a pharmacological formulation encompassing Metformin, Navitoclax/ABT-263, & Dasatinib (MND) and probiotic Lactobacillus rhamnosus increases the expression of tumor suppressor genes, such as RECK, BTG2, p53, and TA-p73/p63, inhibits immune-inhibitory receptors/molecules, targets cancer stem cells, confers protection against chemoresistance and prolongs survival, via up-regulation of its target gene, 29/March/2019, 11.04 pm https://genomediscovery.org/wp-content/uploads/2019/03/A-pharmaceutical-mixture-encompassing-MND-and-or-the-probiotic-Lactobacillus-increase-the-exp-of-a-number-of-tum.-supp.-including-RECK1-BTG2jpg2.jpg 960 720 Dr Boomi's Genom-2-Discovery Center Dr Boomi's Genom-2-Discovery Center https://genomediscovery.org/wp-content/uploads/2019/03/A-pharmaceutical-mixture-encompassing-MND-and-or-the-probiotic-Lactobacillus-increase-the-exp-of-a-number-of-tum.-supp.-including-RECK1-BTG2jpg2.jpg March 29, 2019 March 29, 2019

March 29, 2019

Probiotic-based chemotherapy targeting cancer stem cells and immune-inhibitory receptors in advanced metastatic cancers: A pharmaceutical mixture encompassing a pharmacological formulation encompassing Metformin, Navitoclax/ABT-263, & Dasatinib (MND) and probiotic Lactobacillus rhamnosus increases the expression of tumor suppressor genes, such as Sprouty1/2, hMSH2, p53, and TA-p73/p63, inhibits immune-inhibitory receptors/molecules, targets cancer stem cells, confers protection against chemoresistance and prolongs survival, via up-regulation of its target gene, 29/March/2019, 10.34 pm

Probiotic-based chemotherapy targeting cancer stem cells and immune-inhibitory receptors in advanced metastatic cancers: A pharmaceutical mixture encompassing a pharmacological formulation encompassing Metformin, Navitoclax/ABT-263, & Dasatinib (MND) and probiotic Lactobacillus rhamnosus increases the expression of tumor suppressor genes, such as Sprouty1/2, hMSH2, p53, and TA-p73/p63, inhibits immune-inhibitory receptors/molecules, targets cancer stem cells, confers protection against chemoresistance and prolongs survival, via up-regulation of its target gene, 29/March/2019, 10.34 pm https://genomediscovery.org/wp-content/uploads/2019/03/A-pharmaceutical-mixture-encompassing-MND-and-or-the-probiotic-Lactobacillus-increase-the-exp-of-a-number-of-tum.-supp.-including-Sprouty1.2-and-hMSH2.jpg2_.jpg 960 720 Dr Boomi's Genom-2-Discovery Center Dr Boomi's Genom-2-Discovery Center https://genomediscovery.org/wp-content/uploads/2019/03/A-pharmaceutical-mixture-encompassing-MND-and-or-the-probiotic-Lactobacillus-increase-the-exp-of-a-number-of-tum.-supp.-including-Sprouty1.2-and-hMSH2.jpg2_.jpg March 29, 2019 March 29, 2019

March 11, 2019

Probiotic-based chemotherapy targeting cancer stem cells and immune-inhibitory receptors in advanced ovarian cancer and other metastatic cancers: A pharmaceutical mixture encompassing Olaparib, an FDA-approved poly (adenosine diphosphate-ribose) polymerase inhibitor, and probiotic Lactobacillus rhamnosus increases the expression of tumor suppressor genes, such as RBPMS, RECK, p53, and TA-p73/p63, inhibits immune-inhibitory receptors/molecules, targets ovarian cancer stem cells, confers protection against chemoresistance and prolongs survival, via up-regulation of its target gene, 12/March/2019, 12.11 am

Probiotic-based chemotherapy targeting cancer stem cells and immune-inhibitory receptors in advanced ovarian cancer and other metastatic cancers: A pharmaceutical mixture encompassing Olaparib, an FDA-approved poly (adenosine diphosphate-ribose) polymerase inhibitor, and probiotic Lactobacillus rhamnosus increases the expression of tumor suppressor genes, such as RBPMS, RECK, p53, and TA-p73/p63, inhibits immune-inhibitory receptors/molecules, targets ovarian cancer stem cells, confers protection against chemoresistance and prolongs survival, via up-regulation of its target gene, 12/March/2019, 12.11 am https://genomediscovery.org/wp-content/uploads/2019/03/Olaparib-functions-as-an-anti-metastasis-agent-by-increasing-the-expression-of-tumor-including-RBPMS-RECK-p53-TAp73.p63-and-INK4a.ARF_.jpg 960 720 Dr Boomi's Genom-2-Discovery Center Dr Boomi's Genom-2-Discovery Center https://genomediscovery.org/wp-content/uploads/2019/03/Olaparib-functions-as-an-anti-metastasis-agent-by-increasing-the-expression-of-tumor-including-RBPMS-RECK-p53-TAp73.p63-and-INK4a.ARF_.jpg March 11, 2019 March 11, 2019

Introduction: What they say: A study from the Stephenson Cancer Center at the University of Oklahoma, Oklahoma City (K.M.); University of Milan-Bicocca, European Institute of Oncology Istituto di Ricovero e…

Popular Post